

# 1 Genomic predictors of response to antidepressants in Major depressive disorder 2 (MDD): A GWAS-Based Study on Indian cohort

3  
4 Isha Goel <sup>1,2</sup>, Gagan Hans <sup>1</sup>, Nand Kumar <sup>1,\*</sup>, Subhradip Karmakar <sup>2,\*</sup>

5  
6 1. Department of Psychiatry, All India Institute of Medical Sciences, New Delhi 110029, India

7 2. Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India

8 \* Corresponding Authors

## 9 10 11 Abstract

12  
13 Background: Major depressive disorder (MDD) affects a significant portion of the population,  
14 with approximately 70% of patients not achieving adequate remission using anti-depressant  
15 monotherapy, a condition known as inadequate treatment response (ITR). In the Indian population,  
16 few studies have explored the genetic associations of this response, and those that exist are  
17 underpowered. This study aims to identify single nucleotide variations associated with ITR in the  
18 Indian population. The goal is to develop a population-specific gene panel that can identify  
19 subjects at risk for ITR, allowing alternative treatment modalities.

20  
21 Methods: Subjects satisfying inclusion-exclusion criteria were enrolled for the study following  
22 institutional ethical approval. We recruited 120 subjects with MDD and assessed their response to  
23 monotherapy (Escitalopram) using the Hamilton Depression Rating Scale (HAMD) before and 4-  
24 6 weeks after medication. Responders (n=45) and non-responders (n=75) were genotyped using  
25 the Infinium Global Screening SNP-Array-24 v3.0. A genome-wide association study (GWAS)  
26 was performed to identify SNPs associated with ITR.

27  
28 Results: Twelve lead-significant SNPs with a threshold of  $< 1E-05$  were identified, suggesting an  
29 association with ITR. Among these, four SNPs were located in the intronic/regulatory regions of  
30 the genes *LRSAM1*, *EFCAB2*, *TRIM56* and *ZNF17*. The remaining eight SNPs were near genes  
31 *ALDH1A2*, *LIPC*, *MYOCD*, *SPRY2*, *ANKRD18B*, *CCDC54*, *TNS3*, *ANKRD46*, and *FCRL2*. These  
32 genes are involved in critical functions related to cell signalling, immune response,  
33 neurodevelopment, regulating intracellular levels, and transcription factor binding.

34  
35 Conclusions: Our study identified several novel SNPs that may be associated with ITR in MDD  
36 patients, reported for the first time in an Indian cohort. Further investigations are underway to  
37 determine their clinical significance and potential to be used for screening individuals responding  
38 to drug interventions as user-friendly gene panels.

## 39 40 Keywords


41 Depression, Drug response, Personalized treatment, Genome-wide association study, Selective  
42 serotonin reuptake inhibitors

## 43 1. Introduction

44

45 Unipolar depression, also known as Major Depressive Disorder (MDD), is among the leading  
46 causes of disability worldwide, ranking fourth in terms of disease burden and accounting for 46  
47 million disability-adjusted life-years (DALYs) in 2021. According to the Global Burden of  
48 Disease Study 2021, depression is the fifth leading cause of disability in India, as measured by  
49 DALYs. The prevalence of depressive disorders increased from 3,745 cases per million in 2019  
50 to 4,418 cases per million in 2021, with Major Depressive Disorder (MDD) alone contributing to  
51 over 70% of these cases, affecting nearly 45.4 million individuals in 2021 (Global Burden of  
52 Disease Collaborative Network, 2024). MDD affects individuals across all genders, ages, and  
53 social backgrounds. MDD is characterized by persistent sadness, loss of interest in activities, and  
54 a range of emotional and physical issues, often leading to suicidal thoughts (WHO, 2023).  
55 Symptoms of MDD can vary widely among individuals. First-line antidepressant monotherapy  
56 prescribed includes Selective Serotonin Reuptake Inhibitors (SSRIs) such as citalopram and  
57 escitalopram, and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) like duloxetine and  
58 venlafaxine (Johnson CF et al., 2022). Despite their widespread use, the chronic and episodic  
59 nature of MDD, combined with poor psychosocial functioning, significantly contributes to the  
60 global economic burden. While medications and psychotherapy are effective for many,  
61 approximately 30-50% of depression patients do not achieve sufficient symptom relief with  
62 monotherapy, a condition known as inadequate treatment response (ITR). The situation is  
63 particularly alarming in India, where more than 70% of patients experience inadequate treatment  
64 response (Rafeyan R., et al., 2020; Arvind BA., et al., 2019).

65



66

67

68 Figure 1. Graph showing the numbers of disability-adjusted life-years (DALYs) due to major  
69 depressive disorder in both the global and Indian contexts from 1990 to 2021. (Data and figure  
70 acquired from Global Burden of Disease Collaborative Network, 2024)

71

72 One of the critical challenges in managing MDD is its multifaceted nature, which arises from  
73 diverse causes, coupled with our limited understanding of its pathogenic mechanisms. Apart from  
74 environmental influences like stress and trauma, genomic factors play a crucial role in the  
75 development of depression. Research indicates that depression can be hereditary, with specific  
76 genes involved in neurotransmitter regulation, such as serotonin, linked to a higher risk (Sullivan  
77 et al., 2000). Additionally, genes related to neuroplasticity (e.g., *BDNF*), the immune system (e.g.,

78 *SPPI*), and the stress response (e.g., *5-HTTLPR*) contribute significantly to the complexity of  
79 depression. (Sforzini, L., et al., 2024; Marlene et al., 2023; Caspi, A. et al., 2003). Variants in these  
80 genes can predispose individuals to depression and, importantly, influence how they respond to  
81 antidepressants. The National Institute of Mental Health (NIMH) conducted the sequenced  
82 Treatment Alternatives to Relieve Depression (STARD) study\*, which identified genetic markers  
83 associated with the effectiveness of antidepressant treatments helping to tailor personalized  
84 therapeutic approaches (Laje G., et al., 2009). Table 1 provides a list of genetic variants that have  
85 been associated with the response to antidepressant therapy in STARD\* study and few others  
86 (Francis J. et al., 2006; Lemonde S. et al., 2004; Hong CJ., et al., 2006; Villafuerte SM., et al.,  
87 2009; Kato M., et al., 2009; Paddock S, et al., 2007). The genetic variants identified in the  
88 STARD\* study were primarily based on a population in the United States (Caucasian, Black, and  
89 Hispanic individuals), which may not fully represent the genetic diversity found in the Indian  
90 population. Due to significant genetic differences and unique genetic variants in the Indian  
91 population, the applicability of these findings may vary.

Gene	Genome build (GRCh38)	Nucleotide Change	Region	rsID
SLC6A4	chr17:30221317-30221615	Stin2.9, Stin2.10 and Stin2.12 (9, 10 or 12 copies of a 16–17 bp repeat)	SLC6A4: intronic VNTR polymorphism	STin2
SLC6A4	chr17:30237299	A>G (l/s allele)	SLC6A4 : 2KB Upstream Variant	rs4795541
SLC6A4	chr17:30237328	T>C / T>G	SLC6A4 : 2KB Upstream Variant	rs25531
HTR1A	chr5:63955024	T>G	-	rs1364043
HTR1A	chr5:63962738	C>A / C>G	HTR1A : 2KB Upstream Variant	rs6295
HTR1B	chr6:77463275	G>A / G>C / G>T	HTR1B : Synonymous Variant	rs6298
HTR2A	chr13:46837850	A>C / A>G / A>T	HTR2A : Intron Variant	rs7997012
HTR2A	chr13:46859220	C>A / C>G / C>T	HTR2A : Intron Variant	rs9316233
HTR2A	chr13:46847701	C>T	HTR2A : Intron Variant	rs1923884
ABCB1	chr7:87531245	A>G	ABCB1 : Intron Variant	rs2032583
DTNBP1	chr6:15650901	G>A	DTNBP1 : Intron Variant	rs760761
GRIK4	chr11:120792654	T>C	GRIK4 : Intron Variant	rs1954787
TPH2	chr12:71938143	G>A / G>T	TPH2 : 2KB Upstream Variant	rs4570625
DAOA	chr13:105489886	C>A / C>T	DAOA : Synonymous Variant	rs778294
DISC1	chr1:231818355	C>T	DISC1 : Missense Variant	rs6675281
DISC1	chr1:231827745	C>A / C>T	DISC1 : Intron Variant	rs1000731
FKBP5	chr6:35702206	A>C / A>G / A>T	FKBP5 : Intron Variant	rs4713916
KCNK2	chr1:215000495	C>T	LOC124904510 : Intron Variant	rs2841616
KCNK2	chr1:215239563	G>A / G>C	KCNK2 : Downstream Variant	rs7549184
KCNK2	chr1:215246328	G>A / G>C / G>T	KCNK2 : Downstream Variant	rs10494996
KCNK2	chr1:215017904	G>C / G>T	KCNK2 : Intron Variant	rs2841608
KCNK2	chr1:215077884	G>A / G>C	KCNK2 : Intron Variant	rs12136349
KCNK2	chr1:215152892	G>A / G>T	KCNK2 : Intron Variant	rs10779646

92

93 Table 1: Table listing the details of the variants reported in literature to be associated with SSRI-  
94 treatment response.

95

96 This study aims to address this critical issue within the Indian population, where genetic  
97 associations with treatment response have been minimally explored and existing studies lack

98 sufficient power. By leveraging a genome-wide association study (GWAS), this research seeks to  
99 identify single nucleotide polymorphisms (SNPs) associated with ITR in Indian patients, paving  
100 the way for personalized treatment strategies. Building on this, our study will conduct a  
101 retrospective genotypic analysis of depressed patients treated at AIIMS clinics. By comparing  
102 patients requiring multi-drug therapy to those responding to monotherapy, we aim to validate  
103 reported proprietary markers and discover new ones, enhancing the genetic panel for predicting  
104 treatment response. This approach promises to improve clinical outcomes through earlier and  
105 more accurate identification of patients at risk for ITR, ultimately guiding more effective and  
106 individualized treatment plans.

107

## 108 **2. Materials and methods**

### 109 **2.1 Subjects**

110 The study was conducted at the Department of Biochemistry in collaboration with the  
111 Department of Psychiatry at the All-India Institute of Medical Sciences (AIIMS), New Delhi,  
112 India, from November 2022 to June 2024. Subjects presenting at the psychiatric outpatient  
113 department with symptoms of depressive disorder were assessed based on specific inclusion  
114 and exclusion criteria. Participants aged 18-65 years, who provided informed consent, and had  
115 non-psychotic major depressive disorder (DSM-V), HAMD scores  $\geq 17$ , and no history of  
116 electroconvulsive therapy (ECT) were included. Those recommended for monotherapy  
117 (Escitalopram) treatment or already on multiple antidepressants due to non-response to  
118 escitalopram were further evaluated.


119

120 Exclusion criteria included major comorbidities such as cancer, surgery, heart disease, and  
121 known or suspected pregnancy during the study period. Subjects unwilling to provide consent  
122 were also excluded. Detailed patient information was recorded in both physical files and  
123 electronic documents, encompassing the patient information sheet, informed consent form,  
124 referral form with socio-demographic details, medical history, primary clinical diagnosis, and  
125 medication information. Depression severity was assessed using the 17-item HAMD scale  
126 through structured interviews.

127

128 To determine responders and non-responders to antidepressant treatment, the severity of  
129 patients' depression was evaluated twice using the aforementioned scales at two time points.  
130 The first assessment was conducted on the day of patient enrolment, with those having a  
131 HAMD score  $\geq 17$  proceeding to further evaluation and blood collection (Evaluation I). Blood  
132 samples (4-5 ml) were drawn from consenting patients by an experienced practitioner and  
133 stored in sterilized EDTA vials. Patients were re-evaluated for depression severity after 4-6  
134 weeks of antidepressant treatment using the HAMD scale (Evaluation II). A reduction in  
135 HAMD score of  $\geq 50\%$  categorized patients as responders, while those failing to meet this  
136 criterion were classified as non-responders. Patients already on multiple antidepressant  
137 therapies due to non-response to escitalopram were classified as non-responders to  
138 monotherapy.

139



140  
141 Figure 2: Work flow of sampling with details of Inclusion/Exclusion criteria and Evaluation  
142 metrics for the stratification of patients into responders and non-responder group.  
143

## 144 2.2 Sample preparation

145 Blood samples collected at the OPD were immediately sent to the molecular lab in the  
146 Department of Biochemistry for DNA isolation. Using a genomic DNA extraction kit (Qiagen  
147 QIAamp Blood Midi-Kit – Catalogue no. 51185), genomic DNA (gDNA) was isolated from  
148 the blood following the standard kit protocol. The quality and quantity of the isolated gDNA  
149 were assessed using a spectrophotometer (Nano Drop Technologies, Wilmington, DE, USA)  
150 and gel electrophoresis. A DNA sample with a concentration of 100 ng/ $\mu$ L and an OD value  
151 (260/280 ratio) of approximately 1.8 was considered acceptable in terms of quality.

152 Subsequently, 2 $\mu$ g of purified gDNA was used for genotyping with the Illumina Infinium  
153 Global Screening BeadChip Array v3.0 (Illumina, San Diego, CA, USA). This array enables  
154 the genotyping of over 600,000 highly optimized multi-ethnic, curated clinical variants (based  
155 based on ClinVar, NHGRI-EBI and PharmGKB databases) spanning both coding and non-  
156 coding regions of the human genome. The genotyping data was generated in the form of .idat  
157 files, which were then analysed using Genome Studio 2.0.

## 158 2.3 Quality Control

159 Raw genotyping data files (.dat files) generated from the Illumina GSA bead-chip array were  
160 imported into GenomeStudio (v2.0) software (GenomeStudio Software (illumina.com)) using  
161 the Illumina hg38 manifest file and sample information sheet. SNP calls were generated and  
162 clustered, followed by quality control and filtering based on call rates, strand orientation, and  
163 gender estimation. Metadata was enriched with phenotypes of interest, and the cleaned data  
164 was exported into PLINK format for further processing. Using PLINK v1.9, the genotyping  
165 data underwent quality control procedures, including assessments of SNP and individual  
166 missingness, minor allele frequency, gender correction, heterozygosity, relatedness, and  
167 Hardy-Weinberg equilibrium (HWE) parameters. Highly heterozygous individuals,  
168 duplicates, closely related individuals, and SNPs in build-specific high linkage disequilibrium  
169 (LD) regions were removed.

170

## 171 2.4 Population Stratification and Imputation

172 The LD-pruned data was then checked for outliers using multidimensional scaling (MDS)  
173 analysis based on population stratification methodology, referencing population data from the  
174 1000 Genomes Project phase 3. Outliers were identified using component-wise outlier  
175 detection and manual inspection of the MDS plot. Subjects that failed to follow population  
176 homogeneity were discarded. Phasing and imputation were performed using the Michigan  
177 Imputation Server 2 (Das S., et al., 2016) with the 1000 Genomes Project phase 3 dataset. This  
178 platform uses Eagle v2.4 to estimate haplotype phase and Minimac4 for imputation using a  
179 specific reference panel (HRC or 1000 Genomes). SNPs with  $R^2 < 0.3$  and minor allele  
180 frequency (MAF)  $< 0.05$  were excluded.

181

## 182 2.5 Statistical Analysis and Annotation

183 The filtered SNPs were analysed for binary traits using the PLINK --assoc command, which  
184 employs a chi-squared test to identify SNPs significantly associated with the phenotype of  
185 interest. Quality and association results were visualized through QQ plots and Manhattan plots.  
186 Following this, SNP results were functionally annotated using Annovar to identify known and  
187 novel variants along with their associated genes.

188

## 189 3. Results

### 190 3.1 Patient enrolment

191 Total, 257 patients were screened at the psychiatric outpatient department of AIIMS. Out of  
192 these, 213 patients were enrolled in the study, with the remaining excluded due to age criteria,  
193 comorbidities, or refusal of consent. Within the enrolled group, 11 patients were excluded due  
194 to unsuccessful sample preparation. 82 patients dropped out during follow-up. Ultimately, 120  
195 patients successfully completed all the assessments and medication. Table 2 shows  
196 demographic details of the patients enrolled and their response group based on the HAMD  
197 scale scores after successful evaluations.


Characteristics	Patients N=120	
	Responders N=45	Non-responders N=75
<b>Gender</b>		
Male (57)	29	28
Female (63)	16	47
<b>Age</b>		
18-40 years (81)	31	50
>40 years (39)	14	25

198 Table 2: Demographic characteristics of the patients who have completed assessment.

199 Among the 120 patients studied, 37.5% were categorized as responders, whereas 62.5% were  
200 non-responders. Gender distribution showed that males constituted 47.5% of the total sample,  
201 with 24.2% of them being responders and 23.3% non-responders. Conversely, females made  
202 up 52.5% of the sample, with 13.3% responders and 39.2% non-responders, reflecting a higher  
203 prevalence of depression in females. Age-wise, 67.5% of the patients were between 18-40  
204 years, with 25.8% responders and 41.7% non-responders, indicating a higher impact of  
205 depression in the younger age group. In the older age group (above 40 years), 32.5% of the  
206 patients were represented, with 11.7% being responders and 20.8% non-responders. These  
207 statistics suggest that depression disproportionately affects younger individuals more  
208 significantly.

## 209 3.2 QC and Population stratification

210 Genotyping calls from the raw data of all 120 samples (45 True-Responders, 65 Non-  
211 Responders, and 10 Resistant) were generated using Genome Studio 2.0. Out of the total 120  
212 individuals, two were removed due to high heterozygosity, and one was removed due to  
213 duplicate sampling, resulting in 117 samples being retained for association analysis. SNP call  
214 rates for all individuals exceeded 98%. Of the initial 654,027 SNPs, 400,460 remained after  
215 filtering based on the aforementioned quality control metrics. Utilizing 1000g phase 3  
216 population data, the remaining SNPs were subjected to MDS analysis for the assessment of  
217 population structure and identification of outliers. As shown in figure 3, all the 117 samples  
218 (labelled as OWN) from our study overlapped with individuals from SAS (South Asian)  
219 population that is composed of five sub-populations including Sri Lankan Tamils from the UK,  
220 Indian Telugu from the UK, Gujrati Indian from Houston, Texas, Punjabi from Lahore and  
221 Bengali from Bangladesh; the closest representative of Indian population in 1000 Genome  
222 phase 3 dataset. As inspected manually as well as computationally there were no significant  
223 outliers among the subjects under study, and all were processed further for imputation and  
224 association analysis.



225


226 Figure 3: MDS plot showing the population structure of the 1000 Genome phase 3 data with  
227 individuals from different global populations including European (EUR), American (AMR),  
228 African (AFR), South Asian (SAS), and East Asian (EAS) along with the data of 117  
229 individuals from this study labelled as OWN.

230 **3.3 Phasing and Imputation:** Additional pre-processing steps were performed for  
231 imputation as recommended on the Michigan Server of Imputation, following which 3,82,562  
232 SNPs and 117 individuals passed all the filters and QC. These SNPs were then subjected to  
233 imputation using all the populations in the 1000 Genome phase 3 data. Variants with R2 score  
234 < 0.3 and MAF < 0.05 were filtered out, retaining 67,78,587 imputed SNPs with an average  
235 genotype calling rate of 1.0.


236

237 **3.4 SNPs associated with ITR**

238 Of the total 117 individuals, 73 belonged to the non-responder (non-responders to monotherapy  
239 + those on multi-antidepressant treatment due to non-response to monotherapy) groups and 44  
240 belonged to the responder (responders to monotherapy) group. Association based on binary  
241 (Case/Control) trait was performed using --assoc option in PLINK v1.7. A Quantile-Quantile  
242 Plot was utilized to assess the quality of the data used for association based on Genomic  
243 inflation estimate: lambda (based on median chisq) = 1.0321, which was well within the  
244 acceptable range and represents good quality data, as shown in Figure 4. SNP results were  
245 represented in the form of a Manhattan plot (figure 5) and with a p-value cut-off of  $1E-05$  ( $1 \times$   
246  $10^{-5}$ ), a total of 78 significant variants including 12 lead SNPs were identified, suggestive of a  
247 significant association with ITR. Table 3-4 lists the details of the 12 lead SNPs identified  
248 suggestive of an association with ITR. Complete list of 78 significant variants is provided in  
249 the supplementary file S1.



250 Figure 4: QQ (Quantile-Quantile) plot of Non-Responder vs Responder comparison showing  
251 the quality of the data with Genomic Inflation rate Estimate: Lambda = 1.0321, representing  
252 high-quality data.



253 Figure 5: Manhattan plot demonstrating the relationship between SNPs and non-responders,  
254 highlighting some of the lead SNPs (rsIDs) with  $pval < 1 \times 10^{-5}$ . The green horizontal line at  
255 ( $P = 1E-05$ ) represents the genome-wide significance criterion. Red line represents p-value  
256 cut-off of  $5E-08$ .



Sno	CHR	POS	SNPID	P-value	Minor Allele	Major Allele	Frequency of Minor Allele in Cases	Frequency of Minor Allele in Controls	Odds Ratio	Asian Population Frequency
1	17	12569992	17:12569992:T:C	2.96E-07	C	T	0.1575	0.4659	0.2144	T=0.7148; C=0.2852
2	13	80651301	13:80651301:G:A	4.18E-07	A	G	0.2397	0.5682	0.2396	G=0.66; A=0.34
3	15	58359744	15:58359744:C:CACAA	5.62E-07	CACAA	C	0.03425	0.25	0.1064	ACA=1.00; ACAAACA=0.00
4	9	33653459	9:33653459:G:A	3.42E-06	A	G	0.08904	0.3295	0.1989	G=0.85; A=0.15
5	9	127457711	9:127457711:G:C	4.50E-06	G	C	0.3288	0.6364	0.2799	G=0.94; C=0.06
6	3	107162120	3:107162120:G:A	5.93E-06	A	G	0.2055	0.4886	0.2706	G=0.64; A=0.36
7	7	46940824	7:46940824:T:C	6.33E-06	C	T	0.05479	0.2614	0.1638	T=0.8554; C=0.1446
8	1	245020277	1:245020277:C:G	7.49E-06	C	G	0.06849	0.2841	0.1853	C=0.15; G=0.85
9	8	100440707	8:100440707:C:T	8.30E-06	T	C	0.3699	0.6705	0.2885	C=0.4960; T=0.5040
10	7	101098969	7:101098969:G:A	8.39E-06	A	G	0.5959	0.2955	3.516	G=0.48; A=0.52
11	19	57422202	19:57422202:A:G	8.80E-06	G	A	0.3836	0.1136	4.853	A=0.631; G=0.369
12	1	157733448	1:157733448:T:A	9.79E-06	T	A	0.3288	0.625	0.2939	T=0.38; A=0.62

257 Table 3: List of SNPs significantly associated with ITR in depression patients

Sno	CHR	rsID	Type	Nearest Coding Gene	Nearest Coding Gene Name
1	17	rs4791503	LINC00670 : Intron Variant	MYOCD	myocardin
2	13	rs1176317	Intergenic	SPRY2	sprouty RTK signaling antagonist 2
3	15	rs1261660572	Intergenic	ALDH1A2; LIPC	aldehyde dehydrogenase 1 family member A2; Lipase C
4	9	rs855549	Intergenic	ANKRD18B	ankyrin repeat domain 18B
5	9	rs2243898	LRSAM1 : Intron Variant	LRSAM1	leucine rich repeat and sterile alpha motif containing 1
6	3	rs116643249	LINC00882(ncRNA) : Intron Variant	CCDC54	coiled-coil domain containing 54
7	7	rs11767105	Intergenic	TNS3	tensin 3
8	1	rs901664	EFCAB2 : Intron Variant	EFCAB2	EF-hand calcium binding domain 2
9	8	rs10107200	LOC105375670 : Intron Variant	ANKRD46	ankyrin repeat domain 46
10	7	rs4489253	TRIM56:1000B Downstream Variant	TRIM56	tripartite motif containing 56
11	19	rs10853894	ZNF17 : 500B Downstream Variant	ZNF17	zinc finger protein 17
12	1	rs10430455	Intergenic	FCRL2	Fc receptor like 2

258 Table 4: List of nearest genes of the SNPs significantly associated with ITR in depression  
259 patients

260

261 The association analysis of single nucleotide polymorphisms (SNPs) identified several genetic  
262 variants significantly associated with antidepressant treatment response. Among the most  
263 notable findings, rs4791503 on chromosome 17 exhibited a highly significant p-value of  
264  $2.96 \times 10^{-7}$ . The minor allele (C) was observed at a frequency of 0.1575 in cases compared to  
265 0.4659 in controls, resulting in an odds ratio of 0.2144. This SNP, an intron variant within the  
266 *LINC00670* gene, is situated near the *MYOCD* gene, which encodes myocardin, a critical  
267 regulator of smooth muscle gene expression. Another significant SNP, rs1176317 on  
268 chromosome 13, displayed a p-value of  $4.18 \times 10^{-7}$ . Here, the minor allele (A) was present in  
269 23.97% of cases and 56.82% of controls, yielding an odds ratio of 0.2396. This variant is  
270 adjacent to the *SPRY2* gene, known for its role in modulating receptor tyrosine kinase signaling  
271 pathways. The SNP rs1261660572 on chromosome 15, with a p-value of  $5.62 \times 10^{-7}$ , showed  
272 the minor allele (CACAA) frequency to be 0.03425 in cases versus 0.25 in controls, leading to  
273 an odds ratio of 0.1064. This SNP is located upstream of the *ALDH1A2* gene, which is involved  
274 in retinoic acid biosynthesis.

275 Further significant associations were found with rs855549 on chromosome 9 (p-value  
276  $3.42 \times 10^{-6}$ ), rs2243898 on chromosome 9 (p-value  $4.50 \times 10^{-6}$ ), and rs116643249 on  
277 chromosome 3 (p-value  $5.93 \times 10^{-6}$ ). These SNPs are linked to the *ANKRD18B*, *LRSAMI*, and  
278 *CCDC54* genes, respectively, all of which play essential roles in protein interactions and  
279 signalling pathways. Additionally, the SNPs rs4489253 on chromosome 7 (p-value  $8.39 \times 10^{-6}$ )  
280 and rs10853894 on chromosome 19 (p-value  $8.80 \times 10^{-6}$ ) demonstrated the highest odds ratios  
281 of 3.516 and 4.853, respectively, indicating strong associations with the treatment response.  
282 These variants are situated near the *TRIM56* and *ZNF17* genes, involved in ubiquitination and  
283 transcription regulation, respectively. These findings underscore the potential genetic markers  
284 that can predict antidepressant treatment response. The identified genes are integral to various  
285 biological processes, including gene regulation, signal transduction, and cellular metabolism,  
286 thereby contributing to the observed variability in treatment response among individuals.

#### 287 4. Discussion and limitations

288 Our study represents one of the pioneering GWAS investigations into inadequate drug response  
289 in depression within the Indian population, utilizing the Illumina Infinium SNP-array platform.  
290 The objective was to identify key genetic variations contributing to variability in treatment  
291 response. Subjects were carefully selected based on thorough clinical assessments.

292 Our study has certain limitations, primarily due to the moderate sample size, which is smaller  
293 than typical genome-wide association studies (GWAS). The vast genetic diversity within  
294 India's large population adds complexity, as the diverse genetic backgrounds and ethnicities  
295 across different regions introduce significant variability not fully captured by the SAS sample  
296 in the 1000G population dataset. This variability makes it difficult to generalize our findings  
297 to the entire population and can introduce confounding factors, reducing the study's power to  
298 detect significant associations. Additionally, cultural stigma around psychological disorders in  
299 India often leads to underreporting and a lack of formal diagnoses, affecting the quality and  
300 accuracy of the data. We also witnessed significant dropouts in follow-ups, which is typical in  
301 longitudinal studies. Despite these shortcomings, our results are intriguing and of clinical  
302 significance given the fact that a considerable number of people who die by suicide have a  
303 mental health issue. Identifying individuals at risk early on could avoid such disasters through  
304 proper counselling and other preventive measures.

305 Our study successfully identified several genetic variants associated with treatment response,  
306 underscoring the importance of including diverse populations in genetic research. To our  
307 knowledge, this study is one of the first to explore SNP-based heritability of inadequate drug

308 response in depression among the Indian population. Most previous GWAS studies have  
309 focused on American ancestries. Our findings highlight the need for larger, more inclusive  
310 studies to understand the genetic underpinnings of depression and its treatment response in  
311 diverse populations. This research marks a significant step toward identifying genetic  
312 variations that influence drug response in depression, laying the groundwork for future research  
313 and the potential development of personalized treatment strategies that consider the genetic  
314 diversity of the Indian population.

315 In our study, we identified over 25 significant intergenic variants on chromosome 15, located  
316 near the regulatory regions of genes *ALDH1A2* and *LIPC*. *ALDH1A2* (Aldehyde  
317 Dehydrogenase 1 Family Member A2) encodes an enzyme involved in retinoate signalling,  
318 ESR-mediated signalling, and cofactor metabolism. *LIPC* (Lipase C, hepatic type) plays a  
319 crucial role in plasma lipoprotein assembly, remodelling, and cholesterol metabolism, with  
320 previous studies linking lipoprotein levels to depression and cognitive behaviour (Jia QF et al.,  
321 2020). Additionally, one significant variant on chromosome 9 was located in the intronic region  
322 of the gene *LRSAMI*, which encodes a ring finger protein involved in intracellular trafficking,  
323 antigen processing, signal transduction, cell adhesion, and the adaptive immune response.  
324 Mutations in *LRSAMI* have been linked to neurodegenerative diseases such as Parkinson's  
325 disease (Mishra R et al., 2020).

326 We also discovered four significant intronic variants on chromosome 1 associated with the  
327 *EFCAB2* gene (EF-Hand Calcium Binding Domain 2), which is involved in calcium ion  
328 binding. Although its function is not yet fully determined, the GENDEP clinical trial suggests  
329 its role in neurodevelopment and cognitive function, particularly in axon cargo transport and  
330 neurotransmitter release (Uher, R., 2009; Ren H et al., 2018). Furthermore, a downstream  
331 variant on chromosome 19 (rs10853894) was significantly associated with the *ZNF17* gene, a  
332 DNA-binding transcription factor implicated in numerous essential cellular processes,  
333 including transcriptional regulation, ubiquitin-mediated protein degradation, signal  
334 transduction, actin targeting, DNA repair, and cell migration. ZNF proteins have been  
335 associated with various neuro-related diseases, including Alzheimer's, schizophrenia,  
336 depression, anxiety, trauma, epilepsy, and autism (Bu S et al., 2021).

337 Other notable genes, such as *TRIM56*, *MYOCD*, *SPRY2*, *ANKRD18B*, *CCDC54*, *TNS3*,  
338 *ANKRD46*, and *FCRL2*, were also identified, highlighting their involvement in innate immune  
339 response, nervous system development, PDGFR-beta signalling pathway, FGFR2/3 signalling,  
340 and receptor tyrosine kinase signalling. These findings provide insights into the genetic  
341 underpinnings of drug response in depression, suggesting potential targets for personalized  
342 treatment strategies.

343 Notably, none of the identified SNPs, genes, or loci have been previously reported in earlier  
344 GWAS studies on depression. This discrepancy can be attributed to the fact that most GWAS  
345 research has predominantly focused on populations of American and Caucasian ancestry, with  
346 limited studies conducted on the Asian population, particularly the Indian demographic.  
347 Despite this, the major functional ontologies of the identified genes such as Immune response,  
348 cell signalling, metabolic pathways, and transcriptional activities were found to overlap  
349 significantly with those reported in previous research.

## 350 5. Acknowledgments

351 The authors thank the clinical staff (Psychologists) Praggapti Ghosh, Dr. Pratibha Lamba,  
352 Tanya Bhatia, Geetanjali Arora, and Hafsa Masroor for their contributions to the psychological  
353 assessments. We also acknowledge Saurabh Dubey for his technical support, Shubham Dhiryan  
354 and Komal Kashyap for data entry.

## 355 6. Author Contributions

356 Conceptualization, S.K., N.K. and G.H.; methodology, I.G., S.K., N.K. and G.H.; software,  
357 I.G and S.K.; formal analysis, I.G.; investigation, S.K., G.H.; data curation, I.G., G.H.;  
358 writing—original draft preparation I.G.; writing—review and editing, I.G., S.K., N.K. and  
359 G.H; supervision, S.K., N.K. and G.H; project administration, S.K., N.K. and G.H; funding  
360 acquisition, S.K., N.K.

361

## 362 7. Institutional Review Board Statement

363 Institute Ethics Committee of All India Institute of Medical Sciences, New Delhi gave ethical  
364 approval for this work, file no. IEC-523/05.06.2020, RP-16/2020

365

## 366 8. Informed Consent Statement

367 Informed consent was obtained from all subjects involved in the study.

368

## 369 9. Data Availability Statement

370 All data produced in the present study are available upon reasonable request to the authors.

371

## 372 10. Conflicts of Interest

373 The authors declare no conflict of interest.

374

## 375 11. Funding Statement

376 This research was funded by ICMR to vide project No. 5/4-4/187/M/2020-NCD-II

377

## 378 12. References

379 1. Institute of Health Metrics and Evaluation (2024). Global Health Data Exchange  
380 (GHDx). <https://vizhub.healthdata.org/gbd-results> (Accessed 20 November 2024).

381

382 2. World Health Organization: WHO. (2023, March 31). *Depressive disorder*  
383 (*Depression*). <https://www.who.int/news-room/fact-sheets/detail/depression> (Accessed 20  
384 November 2024).

385

386 3. Johnson CF, Maxwell M, Williams B, Dougall N, MacGillivray S. Dose-response effects of  
387 selective serotonin reuptake inhibitor monotherapy for the treatment of depression:  
388 systematic review of reviews and meta-narrative synthesis. *BMJ Med.* 2022 Dec  
389 1;1(1):e000017 <https://doi.org/10.1136/bmjmed-2021-000017>.

390

391 4. Rafeyan R, Papakostas GI, Jackson WC, et al. Inadequate response to treatment in major  
392 depressive disorder: augmentation and adjunctive strategies. *J Clin*  
393 *Psychiatry.* 2020;81(3):OT19037BR3. <https://doi.org/10.4088/JCP.OT19037BR3>.

394

395 5. Arvind BA, Gururaj G, Loganathan S, Amudhan S, Varghese M, Benegal V, Rao GN,  
396 Kokane AM, B S C, P K D, Ram D, Pathak K, R K LS, Singh LK, Sharma P, Saha PK, C  
397 R, Mehta RY, T M S; NMHS collaborators group. Prevalence and socioeconomic impact of  
398 depressive disorders in India: multisite population-based cross-sectional study. *BMJ Open.*  
399 2019 Jun 27;9(6):e027250. <https://doi.org/10.1136/bmjopen-2018-027250>.

400

401 6. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and  
402 meta-analysis. *Am J Psychiatry.* 2000 Oct;157(10):1552-62.  
403 <https://doi.org/10.1176/appi.ajp.157.10.1552>.

- 404  
405 7. Sforzini, L., Marizzoni, M., Bottanelli, C. *et al.* Transcriptomic profiles in major depressive  
406 disorder: the role of immunometabolic and cell-cycle-related pathways in depression with  
407 different levels of inflammation. *Mol Psychiatry* (2024). [https://doi.org/10.1038/s41380-](https://doi.org/10.1038/s41380-024-02736-w)  
408 [024-02736-w](https://doi.org/10.1038/s41380-024-02736-w)  
409  
410 8. Marlene, Santos., Luís, Lima., Serafim, Carvalho., Jorge, Mota-Pereira., Paulo, Pimentel.,  
411 Dulce, Maia., Diana, Correia., M., Fátima, Barroso., S., Gomes., Agostinho, Cruz., Rui,  
412 Medeiros. (2023). The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1,  
413 MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment  
414 Response Phenotypes. *International Journal of Molecular Sciences*, 24(7):6758-6758.  
415 <https://doi.org/10.3390/ijms24076758>  
416  
417 9. Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., & Poulton, R.  
418 (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT  
419 gene. *Science*, 301(5631), 386-389. <https://doi.org/10.1126/science.1083968>.  
420  
421 10. Laje G, Perlis RH, Rush AJ, McMahon FJ. Pharmacogenetics studies in STAR\*D: strengths,  
422 limitations, and results. *Psychiatr Serv*. 2009 Nov;60(11):1446-57.  
423 <https://doi.org/10.1176/appi.ps.60.11.1446>.  
424  
425 11. Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A, Vrieze S, Chew EY, Levy S,  
426 McGue M, Schlessinger D, Stambolian D, Loh PR, Iacono WG, Swaroop A, Scott LJ, Cucca  
427 F, Kronenberg F, Boehnke M, Abecasis GR, Fuchsberger C. Next-generation genotype  
428 imputation service and methods. *Nature Genetics* 48, 1284–1287 (2016)  
429  
430 12. HAMILTON M. A rating scale for depression. *J Neurol Neurosurg Psychiatry*. 1960  
431 Feb;23(1):56-62. <https://doi.org/10.1136/jnnp.23.1.56>.  
432  
433 13. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR,  
434 Manji H, McMahon FJ. Association of GRIK4 with outcome of antidepressant treatment in  
435 the STAR\*D cohort. *Am J Psychiatry*. 2007 Aug;164(8):1181-8.  
436 <https://doi.org/10.1176/appi.ajp.2007.06111790>.  
437  
438 14. Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamashita M, Hosoi  
439 Y, Azuma J, Kinoshita T, Serretti A. Effect of 5-HT1A gene polymorphisms on  
440 antidepressant response in major depressive disorder. *Am J Med Genet B Neuropsychiatr*  
441 *Genet*. 2009 Jan 5;150B(1):115-23. <https://doi.org/10.1002/ajmg.b.30783>.  
442  
443 15. Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M.  
444 SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. *Psychiatr*  
445 *Genet*. 2009 Dec;19(6):281-91. <https://doi.org/10.1097/YPG.0b013e32832a506e>.  
446  
447 16. Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-  
448 1019G) polymorphism in Taiwan Chinese major depressive disorder. *Pharmacogenomics J*.  
449 2006 Jan-Feb;6(1):27-33. <https://doi.org/10.1038/sj.tpj.6500340>.  
450  
451 17. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(-1019)G 5-HT1A  
452 functional promoter polymorphism with antidepressant response. *Int J*

- 453 Neuropsychopharmacol. 2004 Dec;7(4):501-6.  
454 <https://doi.org/10.1017/S1461145704004699>.  
455
- 456 18. Francis J. McMahon, et al. Variation in the Gene Encoding the Serotonin 2A Receptor Is  
457 Associated with Outcome of Antidepressant Treatment. *The American Journal of Human*  
458 *Genetics* 2006, 78(5):804-814.  
459
- 460 19. Uher, R., Huezio-Diaz, P., Perroud, N. et al. Genetic predictors of response to antidepressants  
461 in the GENDEP project. *Pharmacogenomics J* 9, 225–233 (2009).  
462 <https://doi.org/10.1038/tpj.2009.12>.  
463
- 464 20. Jia QF, Yang HX, Zhuang NN, Yin XY, Zhu ZH, Yuan Y, Yin XL, Wang Y, Cheung EFC,  
465 Chan RCK, Hui L. The role of lipoprotein profile in depression and cognitive performance:  
466 a network analysis. *Sci Rep.* 2020 Nov 26;10(1):20704. [https://doi.org/10.1038/s41598-](https://doi.org/10.1038/s41598-020-77782-9)  
467 [020-77782-9](https://doi.org/10.1038/s41598-020-77782-9).  
468
- 469 21. Mishra, R., Amanullah, A., Upadhyay, A., Dhiman, R., Dubey, A. R., Singh, S., Prasad, A.,  
470 & Mishra, A. (2020). Ubiquitin ligase LRSAM1 suppresses neurodegenerative diseases  
471 linked aberrant proteins induced cell death. *International Journal of Biochemistry & Cell*  
472 *Biology*, 120, 105697. <https://doi.org/10.1016/j.biocel.2020.105697>.  
473
- 474 22. Ren, H., Fabbri, C., Uher, R. et al. Genes associated with anhedonia: a new analysis in a  
475 large clinical trial (GENDEP). *Transl Psychiatry* 8, 150 (2018).  
476 <https://doi.org/10.1038/s41398-018-0198-3>.  
477
- 478 23. Bu S, Lv Y, Liu Y, Qiao S, Wang H. Zinc Finger Proteins in Neuro-Related Diseases  
479 Progression. *Front Neurosci.* 2021 Nov 18;15:760567.  
480 <https://doi.org/10.3389/fnins.2021.760567>.  
481
- 482